M1 Kliniken AG
- WKN: A0STSQ
- ISIN: DE000A0STSQ8
- Land: Deutschland
Nachricht vom 05.10.2017 | 08:51
M1 Kliniken AG successfully completes capital increase
M1 Kliniken AG / Key word(s): Capital Increase
M1 Kliniken AG successfully completes capital increase.
The Company increased its share capital by EUR 1,500,000.00 to EUR 16,500,000.00 by issuing a total of 1,500,000 no-par value bearer shares in exchange for cash contributions, to the exclusion of shareholders' statutory subscription rights, making partial use of authorized capital 2015. The new shares are entitled to dividends as of January 1,2017.
The capital increase was carried out to the maximum possible extent. The placement price determined by the Company's Management Board with the approval of the Supervisory Board was EUR 11.00 per share. Due to the high demand, the new shares were sold to institutional investors as part of an accelerated private placement process. Subject to registration of the capital increase in the commercial register, M1 Klinken AG will receive gross proceeds of approximately EUR 16,500,000.00 from the capital increase.
The new shares are to be included in the open market trading of the Frankfurt Stock Exchange (Basic Standard) without a prospectus. Delivery and settlement of the new shares is expected to take place on October 11, 2017.
The capital increase was accompanied by B. Metzler seel. Sohn & Co. KGaA.
M1 Kliniken AG intends to use the proceeds from the capital increase to finance further growth investments and, in particular, to finance the construction of additional M1 Med-Beauty locations.
M1 Kliniken AG
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.
In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to "qualified investors" within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.
Patrick Brenske, Management Board
|Company:||M1 Kliniken AG|
|Grünauer Straße 5|
|Phone:||+49 (0)30 / 88 70 862-25|
|Fax:||+49 (0)30 / 88 70 862-28|
|Listed:||Regulated Unofficial Market in Dusseldorf, Stuttgart; Open Market (Basic Board) in Frankfurt|
|End of Announcement||DGAP News Service|
M1 Kliniken AG starts international expansion: ...
M1 Kliniken AG opens further specialist centre ...
M1 Kliniken AG: M1 Kliniken AG successfully co ...
M1 Kliniken AG: M1 Kliniken AG decides to impl ...
On growth path with top-class medicine: M1 Kli ...
Der AKTIONÄR News
16. Januar 17:01 800%-Strategie: Union Pacific unter Volldampf
16. Januar 17:00 DAX trotzt dem Brexit-GAU - Kaufsignal in Schlagdistanz
16. Januar 16:48 Okta – Cybersecurity-Spezialist liefert satte Kursgewinne
News im Fokus
Deutsche Post AG: Deutsche Post AG nimmt Stellung zur beabsichtigten Entscheidung zur Preisregulierung
15. Januar 2019, 13:37
Original-Research: aventron AG (von First Berlin Equity Research GmbH): Buy aventron AG
16. Januar 2019